NAD+

Oral NAD+ precursors (NMN, NR, niacin, niacinamide) are prodrugs — they must be converted to NAD+ through enzymatic steps in the gut, liver, and peripheral tissues. The conversion efficiency is meaningful but variable: different tissues express different amounts of the relevant kinases (NAMPT, NRK1/2, NMNAT1-3); first-pass hepatic metabolism processes a large fraction before systemic distribution; and as discussed in the CD38 section, extracellular and blood-compartment NAD+ is subject to rapid CD38-mediated degradation before reaching intracellular pools. Subcutaneous injection of NAD+ itself — the actual molecule, not a precursor — bypasses GI conversion entirely. The NAD+ is absorbed from the SubQ tissue into the bloodstream directly, at essentially 100% bioavailability for the dose injected. Plasma NAD+ peaks within 30-60 minutes of injection versus 2-4 hours for oral precursors. Peak plasma concentrations from SubQ injection are approximately 4-8x higher than equivalent oral doses. This is not simply 'more efficient' — it is a different pharmacokinetic profile with a different shape: sharper acute peak, faster clearance. Whether this pulse pharmacokinetic pattern is more or less therapeutically relevant than sustained oral precursor supplementation is the central clinical question for this delivery route.

SUBQ vs IV vs ORAL — THE DELIVERY COMPARISON

IV NAD+ (500-1,000 mg over 1-4 hours): delivers the molecule directly to the bloodstream at the highest achievable plasma concentrations. Produces the largest acute blood NAD+ spike. Requires clinic visit, IV catheter, extended infusion time (1-4 hours), and costs $200-600 per session. The large volume and concentration can cause infusion-rate-dependent side effects (nausea, chest tightness, warmth) if given too fast. No evidence of clinical superiority over oral for chronic outcomes. SUBCUTANEOUS NAD+ (50-100 mg SubQ injection, self-administered): delivers NAD+ at 100% local bioavailability. Sharper and higher peak plasma NAD+ than oral at equivalent doses. Faster onset than oral. Shorter duration than oral. Can be self-administered at home in under 2 minutes. Costs $50-100/month versus $200-600 per IV session. Side effect profile is primarily injection site reactions rather than systemic infusion reactions. ORAL PRECURSORS (250-1,000 mg NMN/NR daily): sustained release pattern; lower peak plasma NAD+; variable conversion efficiency; more convenient; well-studied in RCTs; cheapest option. The honest comparison: SubQ occupies the middle ground — better bioavailability than oral, far cheaper and more convenient than IV, with a pulse pharmacokinetic profile that may suit specific applications (e.g., pre-exercise, post-stress recovery) better than the trough-and-peak pattern of daily oral dosing.

Injectable NAD+ is supplied as a lyophilised (freeze-dried) sterile powder in sealed glass vials. Unlike NMN or NR, which are oral powder supplements, injectable-grade NAD+ must be manufactured to USP sterile standards — this means endotoxin testing (LAL assay), sterility testing, and pharmaceutical-grade lyophilisation. The quality requirement for an injectable compound is substantially higher than for an oral supplement. Research chemical vendors who supply injectable NAD+ vary enormously in manufacturing standards. The critical distinction: some vendors supply oral-grade NAD+ powder in vials — it may be high-purity NAD+ but manufactured without sterile processing, endotoxin testing, or pharmaceutical-grade lyophilisation. Injecting a non-sterile compound risks infection, abscess, and sepsis. Endotoxin contamination in injectable compounds causes fever, chills, and severe inflammatory reactions within 1-4 hours of injection — the 'pyrogen reaction.' When selecting injectable NAD+, the COA must include: HPLC purity 99%+, mass spectrometry confirming molecular weight (663.43 Da for NAD+), endotoxin testing (LAL assay, <5 EU/mg threshold), and sterility testing. A vendor providing only HPLC + MS without endotoxin testing is providing an incomplete safety package for an injectable compound.

Standard 750 mg NAD+ vial reconstitution: the 750 mg lyophilised powder in its vial appears as a white to off-white cake or powder. The reconstitution procedure follows the standard peptide protocol (see Section 2 of the Mitochondrial Protocol document) with the following NAD+-specific notes:

• Use bacteriostatic water (BAC water) — not sterile water for injection. BAC water contains 0.9% benzyl alcohol as a preservative and is appropriate for multi-dose vials with up to 28 days of use.
• Recommended BAC water volume for a 750 mg vial: 3.75 mL → concentration of 200 mg/mL. This is a practical concentration for the typical 50-100 mg dose range used in SubQ protocols.
• At 200 mg/mL: a 50 mg dose = 0.25 mL (25 units on a U-100 syringe). A 100 mg dose = 0.5 mL (50 units on a U-100 syringe).
• NAD+ in solution is light-sensitive and somewhat less stable than lyophilised peptides. Store reconstituted vials in the refrigerator (2-8°C), away from light, in the original opaque vial or wrapped in foil. Use within 28 days.
• NAD+ reconstituted solution is clear and colourless to slightly yellow. A bright yellow colour is normal and not a quality concern — it reflects the inherent colour of the nicotinamide adenine dinucleotide molecule.

Important reconstitution note specific to NAD+: NAD+ is hygroscopic (absorbs moisture from air) and can degrade in solution if exposed to heat. Allow the lyophilised vial to reach room temperature before opening, to prevent condensation forming on the powder. Inject the BAC water slowly down the side of the vial to minimise turbulence. Do not expose the reconstituted solution to temperatures above 25°C.

Parameter

Value

Vial content

750 mg lyophilised NAD+ powder

BAC water to add

3.75 mL → 200 mg/mL concentration

Starting dose

50 mg per injection (0.25 mL = 25 units on U-100 syringe)

Maintenance dose

50-100 mg per injection (25-50 units on U-100 syringe)

Syringe markings

50 mg = 0.25 mL = 25 units | 100 mg = 0.5 mL = 50 units

Injections per vial

7.5 injections at 100 mg/dose | 15 injections at 50 mg/dose

Frequency

3x per week (Mon/Wed/Fri) — not daily; see titration protocol below

Injection route

SubQ — abdomen or outer thigh; rotate sites every injection

Storage

2-8°C, dark, use within 28 days of reconstitution

Solution appearance

Clear to slightly yellow — normal; discard if cloudy or particulate

SubQ NAD+ uses the same technique as SubQ peptide injection, with two specific considerations: injection speed matters more for NAD+ than for peptides (too fast can cause local burning), and site selection significantly affects comfort.

• Preferred injection sites: Abdomen — pinch 1-2 inches of skin lateral to the navel; outer thigh — the lateral third of the thigh midway between hip and knee. Both sites have sufficient subcutaneous adipose tissue for comfortable absorption.
• Avoid: areas with active skin conditions, scar tissue, previous injection site reactions, or the periumbilical area (within 2 inches of the navel).
• Draw the dose: wipe the vial stopper with an alcohol swab. Draw the calculated volume. At 200 mg/mL: 50 mg = draw to the 25 unit mark on U-100 syringe.
• Injection speed: inject SLOWLY — take 5-10 seconds to push the plunger. NAD+ solution at concentration creates a more noticeable stinging sensation than dilute peptide solutions. Slow injection minimises this. Some users find that warming the syringe briefly between the palms of the hands before injection reduces the sting.
• Rotate sites: use a different spot at each injection — at least 1 inch from the previous injection site. Repeated injection at the same spot causes tissue irritation and localised lipoatrophy over time.
• After injection: gentle pressure with a dry swab for 30 seconds. Do not rub — this disperses the depot and increases the sting.

NAD+ INJECTION BURN — WHAT'S NORMAL AND WHAT ISN'T

SubQ NAD+ has a reputation in the community for being more uncomfortable than peptide injections. This is well-founded and expected: NAD+ at 200 mg/mL creates an osmotic gradient in the injection site that produces a noticeable burning or stinging sensation during and immediately after injection. This is normal. It resolves within 1-5 minutes in most users. What reduces it: diluting to lower concentration (use more BAC water — e.g., 5 mL per 750 mg vial for 150 mg/mL); injecting slower; warming the syringe; choosing abdomen over thigh (abdomen is usually more comfortable). What is NOT normal: burning that persists for more than 15-20 minutes; redness or swelling that spreads beyond a 2-3 cm circle within 30 minutes; fever or systemic chills within 1-4 hours of injection (endotoxin reaction — stop injecting, seek medical care); hard lump persisting for more than 48 hours (lipodystrophy or infection). The normal experience: brief sting during and for 1-5 minutes after injection, small red mark that fades within 1-2 hours.

NAD+ injection naive users should NOT start at full dose. The first injection can produce transient systemic effects — a brief warm flush, mild nausea, or light-headedness — as the acute blood NAD+ elevation affects multiple systems simultaneously. These are not dangerous but can be startling if not expected. A stepwise titration protocol minimises these effects.

Week

Dose

Frequency

Notes

1

25 mg (12-13 units)

1x

First injection only. Assess local and systemic tolerance. Expect mild injection site sting. Possible brief warmth/flush. Take morning, sitting down.

1

25 mg

2x (then 3x)

If Week 1 Day 1 is well-tolerated, add second and third injections at 25 mg during Week 1. Mon/Wed/Fri schedule.

2

50 mg (25 units)

3x/week

Increase to 50 mg. This is a meaningful dose — most clinical applications are studied at this level or above for SubQ. Assess for nausea; take with food if helpful.

3-4

75 mg (37-38 units)

3x/week

Optional intermediate step if sensitive. Skip to 100 mg if 50 mg is well-tolerated.

4+

100 mg (50 units)

3x/week

Maintenance dose. At 750 mg/vial and 3x/week at 100 mg: ~7.5 injections per vial = roughly 2.5-week supply per vial.

Advanced

150-200 mg

3x/week

Some protocols use higher doses. Not well-validated for SubQ specifically. At 200 mg/injection, injection site reactions are more common; splitting into two injection sites simultaneously is sometimes recommended.

TIMING — WHEN TO INJECT SUBQ NAD+

The acute NAD+ elevation from SubQ injection creates a metabolic activation that some users find stimulating. Recommended timing: morning, with or shortly after food. Injecting fasted maximises the plasma NAD+ peak but may increase nausea in sensitive individuals. Injecting in the evening carries the same risk of sleep disruption as high-dose oral NMN taken late (insomnia is reported by some users at higher doses — mechanism unclear, possibly related to sirtuin-mediated circadian clock activation). Morning dosing, consistent time each day, is the practical recommendation. Pre-exercise timing: some users inject 30-60 minutes before exercise to take advantage of the acute NAD+ peak during the workout — theoretically maximising SIRT1 and mitochondrial signalling during energy-demanding activity. This is community practice, not a validated protocol.

Injectable SubQ NAD+ has a different side effect profile from oral NAD+ precursors and from IV NAD+ infusion. Understanding the distinctions matters for appropriate management.

Side Effect

Frequency

Management

When to Seek Help

Injection site sting/burn

Very common (expected)

Inject slower; dilute to 150 mg/mL; warm syringe; use abdomen

If pain persists >20 minutes — unusual

Localised redness at injection site

Common

Rotates with site rotation; cold compress if uncomfortable

If spreading redness or warmth beyond 3-4 cm — possible infection

Brief systemic flush/warmth

Common at higher doses

Titrate slowly; sit during injection; hydrate

If persistent or accompanied by BP symptoms

Mild nausea (first 15-30 min)

Moderate — mainly early titration

Take with food; titrate slowly; start at 25 mg

If persistent vomiting — reduce dose

Headache

Occasional

Hydrate; reduce dose if recurrent

If severe or associated with visual changes

Insomnia

Occasional (higher doses or evening dosing)

Morning-only dosing; reduce to 50 mg if persistent

—

Endotoxin reaction (fever, chills, rigors 1-4 hrs post-injection)

Rare — quality issue

Stop injecting; seek medical care; discard vial

ALWAYS — this indicates contaminated product

Hard lump at injection site persisting >48 hrs

Rare

Review technique; vary sites; take a break

If persistent or accompanied by redness/warmth — possible abscess

This is the most important section for anyone deciding whether to use injectable NAD+ over oral NMN/NR. The honest assessment is that the comparison evidence is limited, and the superiority of injectable NAD+ for long-term clinical outcomes is assumed from pharmacokinetic principles rather than proven in controlled head-to-head trials.

THE HONEST EVIDENCE COMPARISON

WHAT IS ESTABLISHED: (1) SubQ injection of NAD+ produces higher and faster plasma NAD+ peaks than equivalent oral precursor doses. (2) IV NAD+ infusion produces the highest acute plasma NAD+ levels of any delivery route. (3) Oral precursors (NMN, NR) reliably raise blood NAD+ by 40-100% at standard doses in human RCTs — Grade A evidence. (4) The clinical outcomes evidence for NAD+ supplementation comes almost entirely from oral precursor studies — metabolic benefits (Grade B), physical performance (Grade B-modest), liver enzymes (Grade B). WHAT IS NOT ESTABLISHED: (1) Whether the higher acute plasma NAD+ from SubQ injection translates to better intracellular NAD+ delivery than sustained oral precursor supplementation. The key question is pulse vs sustained delivery — like comparing a single large drink of water versus continuous hydration. (2) Whether SubQ NAD+ is superior to oral NMN/NR for any of the clinically meaningful endpoints studied in RCTs (insulin sensitivity, physical performance, liver enzymes). No head-to-head comparison trial has been published. (3) Whether SubQ NAD+ produces different tissue distribution of NAD+ than oral precursors — important given that different tissues may have different conversion efficiencies for NMN vs NR vs NAD+ itself. THE PRACTICAL CONCLUSION: SubQ injectable NAD+ is pharmacologically rational and provides higher bioavailability than oral precursors. For applications requiring rapid NAD+ elevation (post-exercise recovery, acute metabolic stress, clinical deficiency correction), the injectable route is mechanistically preferred. For chronic ongoing anti-aging and longevity support where sustained NAD+ levels matter more than acute peaks, oral precursors at adequate doses are comparably effective and far cheaper. The clinical outcomes evidence sits almost entirely on the oral precursor side of this comparison.

Within the mitochondrial optimisation protocol covered in this series, SubQ injectable NAD+ serves as the foundation substrate layer — delivering NAD+ to the bloodstream as a direct ETC fuel rather than requiring conversion through the oral precursor pathway. The protocol positions it as the most direct route to raising systemic NAD+ rapidly in the Phase 1 build. The 3x/week, 100 mg/injection schedule in the protocol (rather than daily dosing) reflects a balance between pharmacological effect and cost management: at 3x/week, you maintain elevated NAD+ during the most important metabolic windows (workout days, recovery days) without the excessive cost of daily injection. Whether daily 50 mg injections or 3x/week 100 mg injections produce superior NAD+ tissue levels over time has not been studied directly — but the total weekly dose is similar (150 mg/week for 3x100mg vs 350mg/week for daily 50mg), and the 3x/week schedule is more practical and cost-effective.

Integration with the other protocol compounds: NAD+ provides the electron carrier substrate that all five compounds in the stack indirectly benefit from. SS-31 relies on adequate NAD+ flowing through the ETC supercomplexes it stabilises. MOTS-c's AMPK activation drives pathways (fatty acid oxidation, glucose uptake) that consume NADH and regenerate NAD+. BPC-157's angiogenic improvement delivers more oxygen to the mitochondria that depend on NAD+ for ATP synthesis. ATX-304's mitochondrial uncoupling increases NAD+ consumption rate, theoretically creating additional demand for the substrate. The stack is designed such that every other compound either depends on or creates demand for NAD+ — making the SubQ injectable the most direct way to ensure the substrate is not limiting.

Parameter

Details

Compound

NAD+ (Nicotinamide Adenine Dinucleotide) — direct molecule, not a precursor

Form

Lyophilised sterile powder — must be pharmaceutical-grade with endotoxin testing

Vial size (protocol)

750 mg lyophilised vial

Reconstitution

3.75 mL BAC water → 200 mg/mL. Swirl gently; do not shake. Clear to slightly yellow solution is normal.

Starting dose

25 mg (12-13 units on U-100) for first injection

Titration

Week 1: 25 mg 3x/week. Week 2: 50 mg 3x/week. Week 4+: 100 mg 3x/week.

Maintenance dose

100 mg (50 units on U-100), 3x/week, morning

Vial yield at 100 mg

7.5 injections per 750 mg vial (approximately 2.5 weeks supply at 3x/week)

Monthly vials needed

~5 vials/month at 3x/week 100 mg. ~2.5 vials/month at 3x/week 50 mg.

Injection technique

SubQ — abdomen or outer thigh; inject slowly (5-10 seconds); rotate sites

Side effects

Expected: injection site sting (brief, normal). Manage with slower injection and dilution. NOT normal: fever/chills 1-4 hrs post-injection (stop; seek care — endotoxin contamination).

Storage

Lyophilised: cool dark place. Reconstituted: 2-8°C, dark, 28 days.

Timing

Morning, with or without food. Avoid evening dosing (possible insomnia).

Cycle

Continuous — no cycle break required for NAD+ substrate supplementation.

Vendor standard

COA must include: HPLC 99%+, MS (663.43 Da), endotoxin LAL assay <5 EU/mg, sterility testing. Do not inject compounds without endotoxin testing confirmed.

'SubQ injectable NAD+ is the same as just taking NMN — it doesn't matter which I use.' Not true. Direct NAD+ injection delivers the actual molecule with 100% SubQ bioavailability. Oral NMN must be converted to NAD+ through enzymatic steps. The pharmacokinetic profiles differ significantly: sharper acute peak from injection vs sustained slower rise from oral precursors. Whether this translates to better clinical outcomes for chronic use is the open question — but they are not pharmacologically equivalent.

'Injectable NAD+ will definitely work better than oral since it bypasses the gut.' Pharmacokinetically more direct, but 'better' for long-term aging and longevity outcomes hasn't been proven. The controlled clinical trial evidence for NAD+ benefits (metabolic, physical, liver) comes almost entirely from oral precursor studies. The injectable route is more bioavailable per dose; whether this bioavailability advantage translates to superior long-term outcomes vs oral hasn't been tested head-to-head.

'Any NAD+ vial sold as injectable-grade is safe to inject.' False. Injectable-grade specifically requires endotoxin testing (LAL assay) in addition to HPLC and MS purity testing. Some vendors supply high-purity NAD+ powder in vials without sterile manufacturing or endotoxin testing. These are not suitable for injection regardless of HPLC purity. Always verify the COA includes endotoxin data before injecting any compound.

'Higher doses are better — I should inject 500 mg like an IV infusion dose.' SubQ injection cannot be directly compared to IV infusion for high-dose delivery. IV infuses slowly over 1-4 hours into the bloodstream. A 500 mg SubQ injection would create a very high concentration bolus in subcutaneous tissue that would be slowly absorbed — likely causing significant injection site reactions and uncomfortable systemic effects without meaningful pharmacological advantage over a 100 mg dose. SubQ and IV are different delivery mechanisms; the IV dose should not be applied to SubQ administration.

ADDENDUM SUMMARY — INJECTABLE SUBQ NAD+

NAD+ injectable SubQ: direct delivery of the NAD+ molecule; 100% SubQ bioavailability; higher acute plasma peak than oral precursors; onset 30-60 min vs 2-4 hours oral. VIAL: 750 mg lyophilised sterile powder; must be pharmaceutical-grade (HPLC 99%+, MS 663.43 Da, LAL endotoxin <5 EU/mg, sterility — do not inject without endotoxin confirmation). RECONSTITUTION: 3.75 mL BAC water → 200 mg/mL; clear to slightly yellow is normal; 28 days refrigerated. TITRATION: start 25 mg (12-13 units); escalate over 4 weeks to 100 mg (50 units); 3x/week Mon/Wed/Fri. SYRINGE MARKINGS at 200 mg/mL: 50 mg = 25 units; 100 mg = 50 units (U-100 syringe). VIAL YIELD: 7.5 injections per 750 mg vial at 100 mg/dose. COST: ~5 vials/month at 100 mg 3x/wk; at $58-70/500 mg vial, approximately $145-175/month. TECHNIQUE: SubQ abdomen or outer thigh; inject slowly 5-10 seconds; rotate sites; expect brief sting (normal). STOP AND SEEK CARE: fever or chills 1-4 hours after injection = endotoxin reaction from contaminated product. TIMING: morning only; avoid evening (insomnia risk). CYCLE: continuous — no cycle break required. vs IV: SubQ is cheaper, self-administered, more practical; comparable acute bioavailability per dose but lower peak than IV; no evidence of superiority for chronic outcomes. vs ORAL PRECURSORS (NMN/NR): higher and faster peak; same total clinical evidence base (most RCT evidence is on oral side); SubQ preferred for acute applications; oral preferred for chronic convenience and cost.

— End of Injectable SubQ NAD+ Addendum —

THE PEPTIDE BIBLE | NAD+ Injectable SubQ Addendum | For Research & Educational Purposes Only